NCT04049929: A Phase I Study of YY-20394 in Patients With Advanced Solid Tumors

Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Not yet recruiting
Phase 1
Drug Category: Serine-Threonine Kinase Inhibitor

Key Eligibility Criteria:

Gender: All
Age: 18 Years to 85 Years (Adult, Older Adult)
Location of Metastases: 
Additional Notes: 
Exclusions: Patients previously treated with PI3K-delta inhibitors & had disease progression; Patients with central nervous system (CNS) or meningeal metastasis with clinical symptoms- see trial for details

Comments are closed.

Up ↑